MED-EL Elektromedizinische Gerate Ges.m.b.H. v. Advanced Bionics, LLC

District Court, D. Delaware·Decided October 9, 2020·No. 1:18-cv-01530·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

MED-EL ELEKTROMEDIZINISCHE Case No. 1:18-cv-01530-JDW GERÄTE GES.M.B.H. and MED-EL

CORPORATION, USA,

Plaintiffs,

v.

ADVANCED BIONICS, LLC, et. al,

Defendants.

AMENDED MEMORANDUM Pursuant to this Court’s Order dated November 4, 2019 (D.I. 55), Plaintiffs MED-EL Elektromedizinische Geräte Ges.m.b.H. and MED-EL Corporation, USA (collectively, “MedEl”) and Defendants Advanced Bionics, LLC, Advanced Bionics AG, and Sonova AG (together, “AB”) have submitted to the Court for construction ten claim terms from the following US Patent Nos.: (a) 7,076,308; (b) 8,270,647; (c) 7,267,847; (d) 8,634,909; and (e) RE46,057. The patents relate to a range of technologies used in cochlear implants. The Court held a Markman hearing on June 5, 2020. In addition, the parties have submitted to the Court several agreed-upon constructions, which the Court will adopt. I. LEGAL STANDARD “It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWS Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (quote omitted). Claim construction is a matter of law. See Teva Pharm. USA v. Sandoz, Inc., 135 S. Ct. 831, 837 (2015). There is no “magic formula or catechism” for construing a patent claim, nor is a court barred from considering “any particular sources or required to analyze sources in any specific sequence.” Phillips, 415 F.3d at 1323. Instead, a court is free to attach the appropriate weight to appropriate sources “in light of the statutes and policies that inform patent law.” Id. A court generally gives the words of a claim their ordinary and customary meaning, which is the “meaning that the term would have to a person of ordinary skill in the art at the time of the invention, i.e., as of the effective filing date of the patent application.” Id. at 1312-13 (quote

omitted). Usually, a court first considers the claim language; then the remaining intrinsic evidence; and finally, the extrinsic evidence in limited circumstances. See, e.g., Interactive Gift Exp., Inc. v. Compuserve, Inc., 256 F.3d 1323, 1331 (Fed. Cir. 2001). While “the claims themselves provide substantial guidance as to the meaning of particular claim terms,” a court also must consider the context of the surrounding words. Id. at 1314. In addition, the patent specification is “always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). But, while a court must construe claims to be consistent with the specification, the court must “avoid the danger of reading limitations from the specification into the claim,” Phillips,

415 F.3d at 1323. This is a “fine” distinction. Comark Communications, Inc. v. Harris Corp., 156 F.3d 1182, 1186–87 (Fed.Cir.1998). In addition, “[e]ven when the specification describes only a single embodiment, the claims of the patent will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words or expressions of manifest exclusion or restriction. Hill-Rom Svcs., Inc. v. Stryker Corp., 755 F.3d 1367, 1372 (Fed. Cir. 2014) (quote omitted). A court may refer to extrinsic evidence only if the disputed term’s ordinary and accustomed meaning cannot be discerned from the intrinsic evidence. Vitronics, 90 F.3d at 1584. Although a court may not use extrinsic evidence to vary or contradict the claim language, extrinsic materials “may be helpful to explain scientific principles, the meaning of technical terms, and terms of art that appear in the patent and prosecution history,” Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed. Cir. 1995). Extrinsic evidence is used “to ensure that the court’s understanding of the technical aspects of the patent is consistent with that of a person of skill in the art.” Phillips, 415 F.3d at 1318. The Federal Circuit has cautioned against relying upon expert reports and

testimony that is generated for the purpose of litigation because of the likelihood of bias. Id.; see also Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 595, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993) (“Expert evidence can be both powerful and quite misleading because of the difficulty in evaluating it.”) Ultimately, the “construction that stays true to the claim language and most naturally aligns with the patent’s description of the invention will be . . . the correct construction.” Renishaw PLC v. Marposs Societa’ per Anzioni, 158 F.3d 1243, 1250 (Fed. Cir. 1998). It follows that a “claim interpretation that would exclude the inventor’s device is rarely the correct interpretation.” Osram GmbH v. Int’l Trade Comm’n, 505 F.3d 1351, 1358 (Fed. Cir. 2007) (quote omitted.)

Free access — add to your briefcase to read the full text and ask questions with AI

MED-EL Elektromedizinische Gerate Ges.m.b.H. v. Advanced Bionics, LLC, (D. Del. 2020).

MED-EL Elektromedizinische Gerate Ges.m.b.H. v. Advanced Bionics, LLC (MED-EL Elektromedizinische Gerate Ges.m.b.H. v. Advanced Bionics, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
OSRAM GmbH v. International Trade Commission
505 F.3d 1351 (Federal Circuit, 2007)
MBO Laboratories, Inc. v. Becton, Dickinson & Co.
474 F.3d 1323 (Federal Circuit, 2007)
Teg-Paradigm Environmental, Inc. v. United States
465 F.3d 1329 (Federal Circuit, 2006)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
Comark Communications, Inc. v. Harris Corporation
156 F.3d 1182 (Federal Circuit, 1998)
Hill-Rom Services, Inc. v. Stryker Corporation
755 F.3d 1367 (Federal Circuit, 2014)
Beacon Adhesives, Inc. v. United States
134 Fed. Cl. 26 (Federal Claims, 2017)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)